


Kynuramine dihydrobromide

Cat. No.:	HY-119395A
CAS No.:	304-47-2
Molecular Formula:	C ₉ H ₁₄ Br ₂ N ₂ O
Molecular Weight:	326.03
Target:	Monoamine Oxidase
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Kynuramine dihydrobromide, an endogenously occurring amine, is a fluorescent substrate of plasma amine oxidase ^{[1][2]} .								
In Vitro	Kynuramine dihydrobromide inhibits both presynaptic and postsynaptic α -adrenoceptors in vitro ^[2] . Kynuramine dihydrobromide has been shown to act as a partial agonist on serotonin receptors in dog cerebral arteries ^[2] . Kynuramine dihydrobromide (20 μ g/mL) causes a small contraction of the ileum but failed to alter the twitch response to cholinergic stimulation ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Kynuramine dihydrobromide (0.064-8 μ g; ICV; single does) facilitates lordosis behavior in estrogen-primed ovariectomized rats ^[3] . Kynuramine dihydrobromide (1.25-5.0 mg/kg; i.v.; single does) increases heart rate and blood pressure in rats ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Female rats^[3].</td> </tr> <tr> <td>Dosage:</td> <td>0.064, 0.32, 1.6 or 8 μg.</td> </tr> <tr> <td>Administration:</td> <td>Intraventricular injection; single does.</td> </tr> <tr> <td>Result:</td> <td>Produced facilitation of lordosis behavior.</td> </tr> </table>	Animal Model:	Female rats ^[3] .	Dosage:	0.064, 0.32, 1.6 or 8 μ g.	Administration:	Intraventricular injection; single does.	Result:	Produced facilitation of lordosis behavior.
Animal Model:	Female rats ^[3] .								
Dosage:	0.064, 0.32, 1.6 or 8 μ g.								
Administration:	Intraventricular injection; single does.								
Result:	Produced facilitation of lordosis behavior.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male rats (about 200g)^[4].</td> </tr> <tr> <td>Dosage:</td> <td>1.25, 2.5 and 5.0 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; single does.</td> </tr> <tr> <td>Result:</td> <td>Promoted heart rate and blood pressure.</td> </tr> </table>	Animal Model:	Male rats (about 200g) ^[4] .	Dosage:	1.25, 2.5 and 5.0 mg/kg.	Administration:	Intravenous injection; single does.	Result:	Promoted heart rate and blood pressure.
Animal Model:	Male rats (about 200g) ^[4] .								
Dosage:	1.25, 2.5 and 5.0 mg/kg.								
Administration:	Intravenous injection; single does.								
Result:	Promoted heart rate and blood pressure.								

REFERENCES

[1]. J B Massey, et al. Kynuramine, a fluorescent substrate and probe of plasma amine oxidase. J Biol Chem. 1977 Nov 25;252(22):8081-4.

[2]. T D Johnson, An alpha-adrenoceptor inhibitory action of kynuramine. Eur J Pharmacol. 1981 Jul 10;72(4):351-6.

[3]. S D Mendelson, et al. Intraventricular administration of l-kynurenine and kynuramine facilitates lordosis in the female rat. Eur J Pharmacol. 1987 Oct 27;142(3):447-51.

[4]. T D Johnson, et al. Blood pressure and heart rate effects of kynuramine in pithed rats. Eur J Pharmacol. 1983 Feb 18;87(2-3):323-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA